上皮性卵巢癌组织中EGFR、KRAS的表达变化及意义

Expression changes and significance of EGFR and KRAS in epithelial ovarian carcinoma

目的观察表皮生长因子受体(EGFR)、鼠Kirsten肉瘤病毒致癌基因(KRAS)蛋白在上皮性卵巢癌(下称卵巢癌)组织中的表达变化,并探讨其临床意义。方法采用免疫组化SP法检测45例卵巢癌组织中的EGFR、KRAS蛋白,另选18例卵巢良性肿瘤组织和30例正常卵巢组织为对照。结果卵巢癌组织中EGFR、KRAS蛋白表达明显高于卵巢良性肿瘤和正常卵巢组织(P均<0.05)。EGFR阳性表达率与卵巢癌临床分期有关(P<0.05),KRAS蛋白阳性表达率与卵巢癌临床分期、分化程度有关(P<0.05);卵巢癌组织中EGFR与KRAS蛋白表达呈正相关(r=0.613,P<0.05)。结论卵巢癌组织中EGFR、KRAS蛋白表达明显上调,且两者呈正相关关系,在卵巢癌的发生、发展中起重要作用;KRAS蛋白可能为卵巢癌发生发展的始动因素,可作为卵巢癌的早期诊断指标之一。

Objective To observe the expression changes of epidermal growth factor receptor（EGFR） and Kirsten rat sarcoma viral proto-oncogene（KRAS） protein in epihtelial ovarian carcinoma and their clinical significance. Methods The expressions of EGFR and KRAS protein in 45 cases of epithelial ovarian cancer, 18 cases of benign ovarian cystoadenoma and 30 cases of normal ovarian tissue were detected by SP immunohistochemical method. Results The expression of EGFR and KRAS protein in ovarian cancer was markly higher than that in benign and normal ovary tissues（ all P 〈 0. 05 ）. The expression rate of EGFR was correlation with clinical stage（ P 〈 0.05 ）. The expression rate of KRAS protein was significantly correlation with clinical stage,historial classification（P 〈 0.05）. There was positive correlation between EGFR and KRAS （r = 0.613,P 〈 0.05 ）. Conclusions The expression of EGFR and KRAS is obviously up-regulated in epithelial ovarian cancer tissues, which have positive correlation. Both them may play important role in the generation and development of ovarian carcinomas. KRAS may act as a promoter gene of ovarian cancer and be one of the early dignosis index for ovarian cancer.